Welcome to our dedicated page for Carisma Therapeutics news (Ticker: CARM), a resource for investors and traders seeking the latest updates and insights on Carisma Therapeutics stock.
Carisma Therapeutics Inc. (CARM) is a clinical-stage biopharma pioneer developing engineered macrophage therapies for oncology, fibrosis, and autoimmune conditions. This page aggregates all company announcements, providing stakeholders with timely updates on CARM's scientific progress and corporate developments.
Investors and researchers will find essential resources including clinical trial milestones, regulatory updates, and strategic partnership announcements. Track developments related to CARM's CAR-M platform technology, in vivo engineering collaborations, and pipeline prioritization decisions.
Key content categories include quarterly financial reports, preclinical data publications, manufacturing advancements, and executive leadership updates. All materials maintain factual accuracy while avoiding speculative claims about future therapeutic outcomes.
Bookmark this page for streamlined access to CARM's verified news stream. Check regularly for updates on macrophage therapy innovations and their implications for CARM's position in the cell therapy sector.
Carisma Therapeutics (CARM) announced a strategic restructuring, including workforce reduction and evaluation of strategic alternatives to maximize asset value. The company will explore options including asset sales, licensing, partnerships, or potential company sale. Cash reserves are projected to last into H2 2025.
Key developments include:
- Achieved pre-clinical proof of concept for liver fibrosis program CT-2401 in Q2 2024
- Paused planned Phase 1 trial of CT-1119 for mesothelin-positive solid tumors
- Moderna collaboration updates: nominated first GPC3-targeting candidate (June 2024), selected all 12 oncology targets (February 2025), and terminated in vivo oncology field exclusivity
The company has suspended all R&D activities and will retain only essential employees for strategic alternative evaluation.
Carisma Therapeutics (Nasdaq: CARM), a pioneer in macrophage-focused therapeutics, has announced its participation in the upcoming H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference. The company's Co-founder and Chief Scientific Officer, Michael Klichinsky, PharmD, PhD, will be presenting at the conference on Tuesday, February 25 at 10:30 am ET.
Interested parties can access an audio webcast of the presentation through the Company's Investor Events section on their Investor Relations webpage. The recording will remain available for a time after the event.
Carisma Therapeutics (Nasdaq: CARM), a pioneer in macrophage-focused therapeutics, has announced its participation in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference. Steven Kelly, President and CEO, will represent the company at the conference on Tuesday, February 11 at 4:40 pm ET.
The presentation will be accessible via audio webcast through the Company's Investor Events section on their Investor Relations webpage, with -time archive availability following the event.
Carisma Therapeutics (NASDAQ: CARM) announced a strategic restructuring, including discontinuation of CT-0525 development and a 34% workforce reduction. The company will redirect focus to its in vivo macrophage engineering platform for fibrosis, oncology, and autoimmune disease therapies.
Key developments include: plans to nominate a liver fibrosis development candidate in Q1 2025; ongoing collaboration with Moderna on multiple oncology and autoimmune programs; and expected restructuring costs of approximately $2.7 million. Three senior executives, including the CFO, General Counsel, and SVP of Human Resources, will depart by December 31, 2024.
The decision to discontinue the anti-HER2 program was based on competitive landscape assessment and recent developments in anti-HER2 therapies affecting antigen loss/downregulation.
Carisma Therapeutics (Nasdaq: CARM), a clinical-stage biopharmaceutical company specializing in immunotherapies, announced its participation in the 7th Annual Evercore ISI HealthCONx Conference. Steven Kelly, President and CEO, will engage in a fireside chat on December 5th at 9:35 am ET. The event will be accessible via audio webcast on the company's Investor Relations webpage under the Investor Events section, with -time archive availability.
Carisma Therapeutics (NASDAQ: CARM) presented promising preclinical data on engineered macrophages for treating liver fibrosis at AASLD The Liver Meeting® 2024. The research shows that macrophages can be genetically engineered to target specific pathways in liver disease using factors like TIM4, relaxin, and IL10. A single dose of TIM4-expressing macrophages, alone or with relaxin, significantly reduced liver fibrosis in the CDAHFD MASH model. The engineered cells were well-tolerated and outperformed non-engineered cells. The company plans to nominate a development candidate for its liver fibrosis program in Q1 2025.
Carisma Therapeutics (NASDAQ: CARM) announced positive pre-clinical data for its anti-GPC3 in vivo CAR-M therapy for hepatocellular carcinoma (HCC), developed with Moderna. The therapy demonstrated ability to create CAR-M directly in vivo, reprogramming myeloid cells to target GPC3-expressing cancer cells. Pre-clinical results showed specificity for GPC3 tumor antigen with dose-dependent cytotoxicity against GPC3+ tumor cells. In both syngeneic and humanized tumor models, the therapy significantly reduced tumor burden and suppressed liver metastasis. The treatment was well-tolerated in mouse models, showing promise as an off-the-shelf treatment for GPC3+ solid tumors, including HCC.
Carisma Therapeutics reported Q3 2024 financial results with cash and cash equivalents of $26.9 million, expected to fund operations into Q3 2025. Research and development expenses decreased to $11.3 million from $19.6 million year-over-year. The company anticipates initial results from the Phase 1 study of CT-0525 in Q1 2025 and plans to nominate a development candidate for its liver fibrosis program in the same quarter. New preclinical data for anti-GPC3 CAR-M therapy and liver fibrosis will be presented at upcoming scientific meetings. The company recently expanded its collaboration with Moderna to include autoimmune disease targets.
Carisma Therapeutics (Nasdaq: CARM) announced new pre-clinical data presentation on their anti-GPC3 in vivo CAR-M therapy for hepatocellular carcinoma (HCC) at SITC 2024. The therapy, developed with Moderna, uses lipid nanoparticles to deliver mRNA that reprograms endogenous myeloid cells, creating an off-the-shelf treatment approach for GPC3+ solid tumors.
The data, demonstrating robust anti-tumor activity, will be presented on November 8, 2024, at the SITC Annual Meeting in Houston, Texas. The presentation focuses on targeting Glypican-3, a tumor-associated antigen commonly expressed in HCC. Two posters will be presented, including one on the pre-clinical efficacy of anti-GPC3 CAR-M and another on a Phase 1 study of anti-HER2 CAR therapy.
Carisma Therapeutics (Nasdaq: CARM) has announced changes to its Board of Directors. Sohanya Cheng, MBA will join the board effective October 31, 2024, while Michael Torok will step down on the same date due to other professional commitments. Board Chair Sanford Zweifach highlighted Cheng's experience in oncology, leadership, strategic planning, and commercialization as valuable assets for advancing the company's portfolio. Cheng expressed enthusiasm about supporting Carisma's mission in developing innovative immunotherapies and strengthening its position in engineered macrophages.
